疏风解毒胶囊和蒲地蓝消炎口服液治疗成人急性上呼吸道感染的药物经济学评价

Economic evaluation of Shufeng Jiedu capsules versus Pudilan Xiaoyan oral solution for adult patients with acute upper respiratory tract infection

目的:评价疏风解毒胶囊和蒲地蓝消炎口服液治疗成人急性上呼吸道感染的经济性。方法:以中国医疗系统为研究角度,采用前瞻性、观察性试验设计,对接受疏风解毒胶囊(研究组)和蒲地蓝消炎口服液(对照组)治疗的成年急性上呼吸道感染患者进行调查随访。收集患者接受治疗期间的成本和效果数据,进行药物经济学评价。结果:共收集到采用疏风解毒胶囊和蒲地蓝消炎口服液治疗的有效患者各232例和166例。2组的3d痊愈率(P=0.163)、3d有效率(P=0.383)、5d有效率(P=0.616)差异均无显著性(P>0.05);但研究组的5d痊愈率显著高于对照组(P=0.009)。研究组的门诊费用总额(P=0.013)和药品总费用(P=0.005)显著更低。不确定性分析结果和亚组分析结果与基础分析结果基本一致。结论:与蒲地蓝消炎口服液相比疏风解毒胶囊治疗成人急性上呼吸道感染的有效性相当,但是疏风解毒胶囊治疗成人急性上呼吸道感染的成本低于蒲地蓝消炎口服液,因此疏风解毒胶囊治疗成人急性上呼吸道感染更具有经济性。

OBJECTIVE To evaluate the cost-effectiveness of Shufeng Jiedu capsules and Pudilan Xiaoyan oral solution in the treatment of acute upper respiratory tract infection.METHODS A prospective observational study was designed to follow up a cohort of adult patients with acute upper respiratory tract infection treated by Shufeng Jiedu capsules（treatment group）and Pudilan Xiaoyan oral solution（control group）from the perspective of the health care system in China.Cost and effectiveness data were collected from these patients for economic evaluation.RESULTS A total of 232 and 166 patients treated with Shufeng Jiedu capsules and Pudilan Xiaoyan oral solution respectively were included.The remission rate at 3 days（P=0.163）,response rates at 3 and 5 days（P=0.383 and P=0.616）were not significantly different between the two groups.However,the 5-day remission rate of Shufeng Jiedu capsules was significantly higher than that of Pudilan Xiaoyan oral solution（P=0.009）.The total medical cost and drug cost of Shufeng Jiedu capsules group were significantly lower（P=0.013 and P=0.005）.CONCLUSION Compared with Pudilan Xiaoyan oral solution,Shufeng Jiedu capsule are slightly more effective and has higher safety.However,the cost of Shufeng Jiedu capsules is significantly lower.Therefore,Shufeng Jiedu capsule is costeffective for adult patients with acute upper respiratory tract infection.